



EVAS
The New Paradigm
in AAA Therapy


ENDOLOGIX
Innovation that Empowers

Transforming AAA Therapy


Nellix® is the first and only system that treats abdominal aortic aneurysms by sealing the entire aneurysmal sac. Nellix® is designed to eliminate the failure modes and complexity of conventional stent grafts.

Nellix® is designed to provide the following benefits:

- Treat more patients
- Simplify procedure planning
- Reduce secondary interventions



72-year-old male with 5.5cm infrarenal AAA




Complete seal of AAA sac with Nellix® device and absence of lumbar arteries upon completion angiogram

Treat More Patients¹


*Reverse
Tapered Neck*



*Concomitant
Iliac Aneurysm*



*Short Common
Iliac*




Indications for Use

- Aortic neck angulation $\leq 60^\circ$
- Minimum non-aneurysmal aortic neck length ≥ 10 mm
- Aortic neck diameter 18-32 mm*
- Iliac artery diameter 9-35 mm*
- Aneurysm blood lumen ≤ 60 mm

*For 10 mm diameter stents

A New Paradigm in AAA Therapy

Nellix® employs stent and polymer-filled endobags — unlike EVAR, where endografts are built *in vivo*.



Polymer

Polyethylene Glycol (PEG)-based biocompatible and biostable two-part solution mixture. Fills endobags to seal the entire aneurysm and cures in less than 10 minutes. Long-term 5 year performance established with bench, preclinical and CE clinical study.^{2,3}

Stents


Balloon-expandable ePTFE-covered CoCr alloy stents.

Endobags

Durable and biostable polyurethane. Oversized to flow lumen and conformable to seal the entire aneurysm.

Visualization of Nellix® Implant on Follow-up

Nellix® implant features are readily visible for long-term surveillance with CT




The Nellix® EndoVascular Aneurysm Sealing System is not approved by COFEPRIS in Mexico.

Simplify Procedure Planning

Nellix[®] simplifies AAA case planning and procedures with minimal product selection parameters and more predictable procedure times.⁴

Key Procedure Deployment Steps



Introduce catheters and visualize anatomy.



Establish stent flow lumens.




Prefill endobags with saline and confirm seal with angiogram.



Seal entire aneurysm with polymer.

Reduced inventory with only 9 product codes that cover the entire indication


More Predictable Procedure Times⁴





Designed to Reduce Secondary Interventions

Nellix® has demonstrated positive clinical outcomes by mitigating some of the key issues with EVAR including implant migration, endoleaks and secondary interventions.

At Least 1 in 8 Patients Treated with EVAR will Undergo Secondary Intervention Within 5 years⁹⁻¹⁶




Endoleaks are the Leading Cause of Secondary Interventions




Patients With Endoleaks Have Worse Outcomes

Patients with Type II endoleaks are twice as likely to experience sac enlargements or reinterventions¹⁸



Secondary Interventions Are Costly¹⁹

5-Year Cumulative Follow-up Costs Per Patient



EVAS FORWARD

Endologix is continuing to build clinical evidence with the EVAS Forward Global Registry (up to 300 patients at up to 30 sites) and US IDE trial (up to 180 patients at up to 30 sites).

Product Codes

Catheter

Model Number	Product Name	Size
N10-100	Nellix Catheter	10 mm x 100 mm
N10-110	Nellix Catheter	10 mm x 110 mm
N10-120	Nellix Catheter	10 mm x 120 mm
N10-130	Nellix Catheter	10 mm x 130 mm
N10-140	Nellix Catheter	10 mm x 140 mm
N10-150	Nellix Catheter	10 mm x 150 mm
N10-160	Nellix Catheter	10 mm x 160 mm
N10-170	Nellix Catheter	10 mm x 170 mm
N10-180	Nellix Catheter	10 mm x 180 mm

Accessories

Model Number	Product Name	Size
NX-001	Nellix Accessory Kit	N/A
NP-001	Nellix Polymer Dispenser	N/A
NP-002	Nellix Polymer	40 ml

Innovation that Empowers

One of the fastest-growing, publicly traded cardiovascular companies in the world, Endologix is the leading innovator in the treatment of life-threatening aortic aneurysms. By developing and manufacturing minimally invasive solutions that enable aneurysm sealing, Endologix empowers physicians to treat patients with the latest advancements in medical technology.

www.endologix.com/nellix

For Nellix® EndoVascular Aneurysm Sealing System, prior to use, refer to the “Instructions for Use” for complete and specific indications, contraindications, all warnings and precautions. Rx only.

1. Karthikesalingam, A., et al. (2013). “The morphological applicability of a novel endovascular aneurysm sealing (EVAS) system (Nellix) in patients with abdominal aortic aneurysms.” *Eur J Vasc Endovasc Surg* 46(4): 440-445.
2. Data on File. Biological Evaluation Report for Endologix Nellix Implant Device. July 2013.
3. Data on File. Report 12-0806-N1.
4. CP-0010 Data Tables. Nellix Post Market Registry: EVAS Global Interim Data Analysis Tables. March 31st, 2014.
5. W.L. Gore & Associates. Instructions for Use for: Gore Excluder AAA Endoprosthesis. April 2009.
6. Stokmans et al. Early results from the ENGAGE registry. *Eur J Vasc Endovasc Surg*. 2012 Oct;44(4):369-75
7. Mertens et al. Long-term results after endovascular AAA repair using the Cook Zenith endograft. *J Vasc Surg* 2011;54:48-57
8. Wang GJ, and Carpenter JP. The Powerlink System for Endovascular AAA Repair: Six-year Results. *J Vasc Surg* 2008;48:535-45.
9. De Bruin, J. L., et al. (2010). “Long-term outcome of open or endovascular repair of abdominal aortic aneurysm.” *N Engl J Med* 362(20): 1881-1889.
10. United Kingdom, E. T. I., et al. (2010). “Endovascular repair of aortic aneurysm in patients physically ineligible for open repair.” *N Engl J Med* 362(20): 1872-1880.
11. United Kingdom, E. T. I., et al. (2010). “Endovascular versus open repair of abdominal aortic aneurysm.” *N Engl J Med* 362(20): 1863-1871.
12. Verzini, F., et al. (2014). “Abdominal aortic endografting beyond the trials: a 15-year single-center experience comparing newer to older generation stent-grafts.” *J Endovasc Ther* 21(3): 439-447.
13. Al-Jubouri, M., et al. (2013). “Reintervention after EVAR and open surgical repair of AAA: a 15-year experience.” *Ann Surg* 258(4): 652-657; discussion 657-658.
14. Abbruzzese, T. A., et al. (2008). “Outcomes following endovascular abdominal aortic aneurysm repair (EVAR): an anatomic and device-specific analysis.” *J Vasc Surg* 48(1): 19-28.
15. Dias, N. V., et al. (2009). “Is there a benefit of frequent CT follow-up after EVAR?” *Eur J Vasc Endovasc Surg* 37(4): 425-430.
16. Conrad, M. F., et al. (2009). “Secondary intervention after endovascular abdominal aortic aneurysm repair.” *Ann Surg* 250(3): 383-389.
17. Ozdemir et al. Embolisation of Type 2 endoleaks after endovascular aneurysm repair. *J Cardiovasc Surg (Tonino)*. 2013; 54(4): 485-90.
18. El Batti, S et al. Type II endoleaks after endovascular repair of abdominal aortic aneurysm are not always a benign condition. *J Vasc Surg* 2013;57:1291-8
19. Noll RE, et al. Long-term post placement cost after endovascular aneurysm repair. *J Vasc Surg* 2007;46:9-15

ENDOLOGIX
Innovation that Empowers